BBCMF (Lir Life Sciences) LT-Debt-to-Total-Asset: 0.00 (As of Jan. 2026)


BBCMF Lir Life Sciences Corp BBCMF
15 GF Score
Price $0.05
View Full Analysis

What is Lir Life Sciences LT-Debt-to-Total-Asset?

Lir Life Sciences BBCMF -80.00% 15 LT-Debt-to-Total-Asset is 0.00 as of Jan. 2026. GuruFocus rates BBCMF with a GF Score™ of 15/100.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Lir Life Sciences's long-term debt to total assests ratio for the quarter that ended in Jan. 2026 was 0.00.

Lir Life Sciences's long-term debt to total assets ratio stayed the same from Jan. 2025 (0.00) to Jan. 2026 (0.00).

Lir Life Sciences  (OTCPK:BBCMF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Lir Life Sciences LT-Debt-to-Total-Asset Related Terms

Lir Life Sciences LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Lir Life Sciences's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lir Life Sciences LT-Debt-to-Total-Asset Chart

Lir Life Sciences Annual Data
Trend Apr24 Apr25
LT-Debt-to-Total-Asset
0.00 0.00

Lir Life Sciences Quarterly Data
Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
BBCMF
15GF Score
Lir Life Sciences Corp BBCMF
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lir Life Sciences LT-Debt-to-Total-Asset Calculation

Lir Life Sciences's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Apr. 2025 is calculated as

LT Debt to Total Assets (A: Apr. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Apr. 2025 )/Total Assets (A: Apr. 2025 )
=0/0.087
=

Lir Life Sciences's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jan. 2026 is calculated as

LT Debt to Total Assets (Q: Jan. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Jan. 2026 )/Total Assets (Q: Jan. 2026 )
=0/0.829
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
Lir Life Sciences (BBCMF) has a LT-Debt-to-Total-Asset of 0.00 as of Jan. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Lir Life Sciences and its competitors.
Is Lir Life Sciences' LT-Debt-to-Total-Asset too high?
Lir Life Sciences' current LT-Debt-to-Total-Asset is 0.00. Overall, Lir Life Sciences has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Lir Life Sciences' LT-Debt-to-Total-Asset compare to VRTX and REGN?
Lir Life Sciences' LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Lir Life Sciences and its competitors. Lir Life Sciences's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lir Life Sciences stock overvalued right now?
Lir Life Sciences (BBCMF) has a current LT-Debt-to-Total-Asset of 0.00. The current LT-Debt-to-Total-Asset is 0.00. Lir Life Sciences' overall GF Score™ is 15/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Lir Life Sciences (BBCMF), the current LT-Debt-to-Total-Asset is 0.00 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lir Life Sciences Business Description

Other Exchanges N790:GermanySKNY:Canada
Address 505-1505 West 2nd Avenue, Vancouver, BC, CAN, V6J 1H2
Lir Life Sciences Corp is a biotechnology company developing transdermal and sublingual drug-delivery technologies for GLP-1-based obesity therapies, with the focus of improving accessibility and patient experience.
15GF Score

Get the complete analysis for BBCMF

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.05
Price